Abstract 639
Background
The prevalence of cognitive impairment is known to be high, but the knowledge of its correlates with lipid peroxidation is limited. The mechanisms responsible for the development of cognitive impairment have been discussed widely, and emerging evidence suggests a significant role of lipid peroxidation as well as vascular inflammation as main contributors to cognitive impairment. We aimed to explore the relationship between lipid peroxidation and the presence of cognitive impairment in patients with brain cancers during cancer-related therapy.
Methods
58 first-ever brain cancer patients without previous cognitive impairment were consecutively enrolled in the current study. The levels of lipid peroxidation were evaluated by looking at the total cholesterol (TC) to high-density lipoprotein (HDL)-cholesterol (TC/HDL-c), low-density lipoprotein (LDL)-cholesterol to HDL-cholesterol (LDL-c/HDL-c), and triglycerides to HDL-cholesterol (TG/HDL-c) at the same time as performing a cognitive impairment test. The lipid peroxidation was measured at two times, within 24 h after admission and 3 months after recieving cancer-related therapy. Cognition function was evaluated by the Mini-Mental State Examination (MMSE) at the same time as lipid peroxidation evaluation.
Results
In this study, all patients were homogeneous in terms of general characteristics, tumor histology types, severity, and location. The patients were classified as cognitively impaired (n = 15, 25.9%) or non-cognitively impaired (n = 43, 74.1%) at 3 month after recieving cancer-related therapy. At admission time, the serum levels of lipid peroxidation were normal values in all patients but the levels were increased at 3 months after brain cancer onset in cognitively impaired groups. The level of lipid peroxidation was significantly different both with and without cognitive impairment groups at 3 months after brain cancer onset (p < 0.001). There was no significant difference between the two groups in tumor histology types, severity, and location.
Conclusions
Lipid peroxidation will need to be considered as a potential indicator for the management of cognitive impairment in early brain cancer stages.
Clinical trial identification
Legal entity responsible for the study
Kim Sanghee.
Funding
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP; Ministry of Science, ICT & Future Planning) (No. NRF-2017R1C1B5016280).
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.